Atlas Trials

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

Clinical trial NCT07615348 · RECRUITING

Trial details

NCT number
NCT07615348
Sponsor
Jinling Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Clear Cell Renal Cell Carcinoma
Start date
2026-06-16
Primary completion
2028-08-10
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.